Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

4,510 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S, Takeuchi S, Nakagawa T, Yamada T. Yano S, et al. Among authors: nakagawa t. Cancer Sci. 2012 Jul;103(7):1189-94. doi: 10.1111/j.1349-7006.2012.02279.x. Epub 2012 May 9. Cancer Sci. 2012. PMID: 22435662 Free PMC article. Review.
(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y, Shimizu M, Adachi S, Sakai H, Nakagawa T, Yasuda Y, Tsurumi H, Hara Y, Moriwaki H. Shirakami Y, et al. Among authors: nakagawa t. Cancer Sci. 2009 Oct;100(10):1957-62. doi: 10.1111/j.1349-7006.2009.01241.x. Epub 2009 Jun 4. Cancer Sci. 2009. PMID: 19558547
E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H. Nakagawa T, et al. Cancer Sci. 2010 Jan;101(1):210-5. doi: 10.1111/j.1349-7006.2009.01343.x. Epub 2009 Sep 2. Cancer Sci. 2010. PMID: 19832844
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Wang W, et al. Among authors: nakagawa t. Clin Cancer Res. 2012 Mar 15;18(6):1663-71. doi: 10.1158/1078-0432.CCR-11-1171. Epub 2012 Feb 8. Clin Cancer Res. 2012. PMID: 22317763
Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma.
Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, Sasano H, Nakagawa T, Satoh K, Tanaka N, Kubo H, Motohashi H, Yamamoto M. Inoue D, et al. Among authors: nakagawa t. Cancer Sci. 2012 Apr;103(4):760-6. doi: 10.1111/j.1349-7006.2012.02216.x. Epub 2012 Feb 21. Cancer Sci. 2012. PMID: 22320446 Free PMC article.
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S. Yamada T, et al. Among authors: nakagawa t. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2. Clin Cancer Res. 2012. PMID: 22553343
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S. Koizumi H, et al. Among authors: nakagawa t. J Thorac Oncol. 2012 Jul;7(7):1078-85. doi: 10.1097/JTO.0b013e3182519a2c. J Thorac Oncol. 2012. PMID: 22592212
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Takeuchi S, et al. Among authors: nakagawa t. Am J Pathol. 2012 Sep;181(3):1034-43. doi: 10.1016/j.ajpath.2012.05.023. Epub 2012 Jul 9. Am J Pathol. 2012. PMID: 22789825
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Nakagawa T, et al. Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25. Mol Cancer Ther. 2012. PMID: 22844075
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. Sano T, et al. Among authors: nakagawa t. Int J Cancer. 2013 Jul 15;133(2):505-13. doi: 10.1002/ijc.28034. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23319394
4,510 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback